TOUR006 for Chronic Kidney Disease
(TRANQUILITY Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for TOUR006 (PF-04236921) in treating chronic kidney disease?
Is the drug TOUR006 (PF-04236921) a promising treatment for Chronic Kidney Disease?
The information provided does not directly address the effectiveness or promise of the drug TOUR006 (PF-04236921) for treating Chronic Kidney Disease. The articles focus on screening, management, and the public health impact of CKD, but do not mention TOUR006 specifically. Therefore, based on the given information, we cannot determine if TOUR006 is a promising treatment.678910
What data supports the idea that TOUR006 for Chronic Kidney Disease is an effective treatment?
The available research does not provide specific data on the effectiveness of TOUR006 for treating Chronic Kidney Disease. The articles focus on other aspects of kidney disease management, such as economic evaluations, surrogate endpoints in clinical trials, and the benefits of early nephrological care. Without direct evidence from these studies, we cannot conclude the effectiveness of TOUR006 for this condition.1112131415
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Tourmaline Bio
Are You a Good Fit for This Trial?
This trial is for adults over 18 with chronic kidney disease who have an eGFR between ≥15 and <60 mL/min/1.73 m2 and elevated hs-CRP levels (≥2.0 mg/L but <15 mg/L). Participants must have received a COVID-19 vaccine at least 30 days prior to screening and agree to follow contraception guidelines.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive subcutaneous administration of TOUR006 or placebo at specified intervals
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TOUR006
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tourmaline Bio, Inc.
Lead Sponsor